GlaxoSmithKline ($GSK) says "unexpected global demand" for its meningitis B vaccine Bexsero has resulted in "supply constraints," which in turn has led to a shortage for private clinics in the U.K. The U.K.-based drugmaker told FierceVaccines that it hopes to have the situation resolved by summer. The drugmaker says the shortage is not affecting its agreement with the U.K. National Health Service, struck last year, to create the world's first national meningitis B vaccination program. GSK got the vaccine in its asset swap with Novartis ($NVS). The FDA approved the jab a year ago. The U.K. vax program began in the fall with the vaccine being offered to British infants at two months, four months and 12 to 13 months. More from FierceVaccines
> With a GMP certificate in hand from China Food and Drug Agency, China's Sinovac ($SVA) says it has started commercial production of its enterovirus 71 ("EV71") vaccine. Release
> Indonesia's Kalbe Farma said it expect to complete this year a plant in Cikarang, West Java, that will produce a biosimilar of Shire's ($SHPG) Dynepo. Story
> French CMO Novasep is building a new synthesis laboratory and a kilo lab for its U.S. facility near Philadelphia. Release
> Hong Kong-listed 3SBio is raising its stake in Shanghai CP Guojian Pharmaceutical, picking up a manufacturing platform for the company's Phase I monoclonal antibody anti-TNF alpha candidates for the treatment of rheumatoid arthritis in the process. Story